OP0160: Hydroxychloroquine blood levels and risk of thrombotic events in systemic lupus erythematosus (Dr. Michelle A Petri, USA).
OP0161: Association of baseline cytotoxic gene expression with ustekinumab response in systemic lupus erythematosus (Dr. Loqmane Seridi, USA).
OP0162: Abatacept treatment for patients with early active primary Sjögren’s syndrome: open-label extension phase of a randomized controlled phase III trial (MD Jolien F. van Nimwegen, Niederlande).
OP0163:2019 update of the joint European league against rheumatism and European renal association – European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis (MD Antonis Fanouriakis, Griechenland).
OP0164: BLISS-LN: A randomised, double-blind, placebo-controlled phase 3 trial of intravenous belimumab in patients with active lupus nephritis (MD Richard Furie, USA).
OP0165: Long-term outcome of a randomized controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy of severe lupus nephritis (Dr. Chi Chiu Mok, Hong Kong).
OP0167: Successful withdrawal of mycophenolate mofetil in quiescent SLE: Results from a randomized trial (Dr. Eliza Chakravarty, USA).